Headshot of Dr. Matthew Solhjem with The Oregon Clinic Radiation Oncology

Matthew Solhjem MD

Headshot of Dr. Matthew Solhjem with The Oregon Clinic Radiation Oncology

Matthew Solhjem MD

TEL: 503-215-6029
FAX: 503-215-6387

We treat each patient as a whole person. My team and I provide state of the art, compassionate, evidence-based care.

Dr. Matthew Solhjem is a board-certified radiation oncologist at The Oregon Clinic who cares for patients with prostate, gastrointestinal and lung cancers, as well as benign and malignant brain tumors.

Dr. Solhjem has advanced training in prostate cancer treatment. He is highly experienced with high dose rate (HDR) brachytherapy, and has performed over 200 prostate HDR brachytherapy procedures. He is the only physician performing this treatment in Oregon. In addition to brachytherapy, Dr. Solhjem is experienced in MRI-guided and CT-guided stereotactic body radiation therapy (SBRT) for prostate cancer.

Barrigel Center of Excellence logo

Dr. Solhjem uses Barrigel rectal spacing to help reduce radiation side effects and rectal complications during and after prostate cancer treatment. He is the only physician in the Pacific Northwest to hold the designation of Barrigel Center of Excellence in recognition of his advanced technique training, high level of skill and experience with the procedure, and commitment to patient education and better outcomes. He continues to build on this experience through ongoing training in prostate cancer treatment and rectal spacing.

Dr. Solhjem is part of the Alliance network for cooperative group studies and a former Principal Investigator for Radiation Therapy Oncology Group studies. He is interested in enrolling patients in clinical studies and has published research on prostate seed implants and HDR brachytherapy for uterine cancer.

In his free time, Dr. Solhjem enjoys spending time with his kids and sailing.

Other Activities

Member, American Brachytherapy Society

Fellow, American Board of Radiology

EDUCATION & TRAINING

Residency, Radiation Oncology, Mayo Clinic, 2005

Internship, Transitional Medicine, Meritcare Medical Center, 2001

MD, University of Minnesota, 2000

BA, University of Minnesota, 1996

BOARD CERTIFICATION

Radiation Oncology

HONORS

Barrigel Center of Excellence

National Consumer Advisory Board, “America’s Best Physicians 2015”

Portland Monthly Magazine, “Top Doctors” 2013, 2024, 2025

Radiological Society of North America (RSNA) Roentgen Resident Research Award

Chief Resident, Radiation Oncology, Mayo Clinic

Internship, “Resident of the Year” Award

Phi Beta Kappa, University of Minnesota

Summa Cum Laude, University of Minnesota

Publications

Yamazaki T, Gunderson AJ, Gilchrist M, Whiteford M, Kiely MX, Hayman A, O’Brien D, Ahmad R, Manchio JV, Fox N, McCarty K, Phillips M, Brosnan E, Vaccaro G, Li R, Simon M, Bernstein E, McCormick M, Yamasaki L, Wu Y, Drokin A, Carnahan T, To Y, Redmond WL, Lee B, Louie J, Hansen E, Solhjem MC, Cramer J, Urba WJ, Gough MJ, Crittenden MR, Young KH. Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial. Lancet Oncol 2022; 23: 1189-1200. 

Crocenzi T, Cottam B, Newell P, Wolf R, Hansen P, Hammill C, Solhjem M, To Y, Greathouse A, Tormoen G, Jutric Z, Young K, Bahjat K, Gough M, Crittenden M. A Hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation of borderline resectable and locally advanced pancreatic adenocarcinoma. J Immunother Cancer 2016 15; 4:45. 

Glass J, Won M, Schultz C, Brat D, Bartlett N, Suh J, Werner-Wasik M, Fisher B, Liepman M, Augspurger M, Bokstein F, Bovi J, Solhjem M, Mehta M. Phase I and II Study of Induction Chemotherapy with Methotrexate, Rituximab, and Temozolomide, Followed by Whole-Brain Radiotherapy and Post-Irradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. J Clinical Oncology 2016; 34(14): 1620-1625. 

Davis BJ, Leenstra JL, Wilson TM, Mynderse LA, Solhjem MC, Herman MG, Hillman DW, Allen-Ziegler KL, Cheville JC, King BF, Holmes III DR. (2014) Prostate Volume in Patients Undergoing Primary Surgical or Radiotherapeutic Management of Localized Adenocarcinoma: Implications for Design of Minimally Invasive Imaging and Treatment Devices for the Prostate. OMICS J Radiol S1:001. doi: 10.4172/2167-7964.S1-001 (in press). 

Seung S, Perrone M, Solhjem M, Salvage SBRT for Previously Irradiated Lung Cancer. Int J Radiat Oncol Biol Phys 2008; 78(3) supplement, Abstract 2745: S537-8. 

Seung S, Bae J, Solhjem M, Bader S, Gannett D, Hansen E, Louie J, Underhill K, Cha C. Intensity-modulated radiotherapy for head-and-neck cancer in the community setting. Int J Radiat Oncol Biol Phys 2008; 72(4): 1075-1081. 

Solhjem MC, Petersen IA, Haddock MG. Vaginal HDR brachytherapy alone is sufficient for surgical Stage I endometrial cancer. Int J Radiat Oncol Biol Phys 2005; 62(5): 1379-1384. 

Solhjem MC, Davis BJ, Pisansky TM, Wilson TM, Mynderse LA, Hillman DW, Herman MG, King BF. Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression. Cancer J 2004; 10(6): 343-348. 

Solhjem MC, Davis BJ, Pisansky TM, Wilson TM, Mynderse LA, Herman MG, King BF, Geyer SM. Prostate volume measurement by transrectal ultrasound and computed tomography before and after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004; 60(3): 767-776. 

Solhjem, MC, Davis BJ, Wilson TM, Mynderse LA. A protocol evaluating the feasibility of intraoperative TRUS-fluoroscopic image fusion and CT-based dosimetry in patients undergoing permanent prostate brachytherapy for prostate cancer. Mayo Clinic Protocol. 

Solhjem MC, Petersen IA, Haddock MG. Vaginal cuff HDR brachytherapy alone is sufficient adjuvant treatment for patients with surgical stage I endometrial cancer (Abstr. 139) Int J Radiat Oncol Biol Phys 2004; 60 (Suppl. 1): S213. ORAL PAPER PRESENTATION and Selected for Discussion, 46th Annual Meeting of the ASTRO, October 6, 2004, Atlanta, GA. 

Solhjem MC, Davis BJ, Schatz SM, Wilson TM, Mynderse LA, Hillman DW. The effect of neoadjuvant cytoreductive hormonal therapy (nHT) on prostate volume (PV), prostatic edema, and urinary morbidity after permanent prostate brachytherapy (PPB). The Cancer Journal 2004; 10(S1): 33-34. ORAL PAPER PRESENTATION, 86th Annual Meeting of the American Radium Society (ARS), May 4, 2004. 

Solhjem MC, Davis BJ, Pisansky TM, Wilson TM, Mynderse LA, Herman MG, King BF, Geyer SM. Can post-permanent prostate brachytherapy trans-rectal ultrasound and computed tomography (CT) image fusion improve reproducibility of post-implant dosimetry? Proceedings of the 89th Annual Meeting and Scientific Assembly of the Radiological Society of North America (RSNA), Chicago, IL, 2003, p. 154. ORAL POSTER PRESENTATION, December 4, 2003.